RecruitingPHASE1, PHASE2NCT06351592

First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Regeneron Pharmaceuticals
Principal Investigator: Clinical Trial Management
Regeneron Pharmaceuticals
Intervention: ALN-SOD(drug)
Enrollment: 42 enrolled
Eligibility: 18 years · All sexes
Timeline: 2024 – 2031

Study locations (16)

Concord Repatriation General Hospital, Concord, New South Wales, Australia
Macquarie University, Sydney, New South Wales, Australia
Sunshine Coast University Hospital, Birtinya, Queensland, Australia
KU Leuven, Leuven, Vlaams-Brabant, Belgium
University of Alberta Hospital, Edmonton, Division of Neurology, Edmonton, Alberta, Canada
University Hospital - London Health Sciences Centre, London, Ontario, Canada
Sunnybrook Research Institute, Toronto, Ontario, Canada
Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada
Hokkaido University Hospital, Sapporo, Hokkaido, Japan
Tokushima University Hospital, Tokushima, Tokushima, Japan
Toho University Omori Medical Center, Ōta-ku, Tokyo, Japan
Kyoto University Hospital, Kyoto, Japan
Hanyang University Seoul Hospital, Seoul, South Korea
Seoul National University Hospital, Seoul, South Korea
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan
+1 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06351592 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis →

← Back to all trials